Pfizer’s 7% dividend yield reflects market concerns over sustainability despite a 57% payout ratio based on $2.99 EPS estimates.
Pfizer’s 7% dividend yield has attracted income investors, but the elevated yield may signal underlying risks. The company’s payout ratio stands at 57%, based on projected earnings of $2.99 per share this year, a figure analysts consider manageable for now. Pfizer has reiterated its commitment to the dividend, calling it a priority during its first-quarter 2026 earnings call in May.
The pharmaceutical giant’s financials benefited from COVID-19 vaccine and treatment sales, but revenue has declined as demand waned. With the stock trading 60% below its 2022 high, the dividend provides a critical income stream for shareholders facing unrealized losses. However, future payout sustainability remains uncertain amid shifting market dynamics.
No immediate market reaction was reported, but the high yield underscores investor caution about long-term dividend stability.